InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,618.80
(
0.05%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.71
(
-0.19%
)
Bitcoin
62,917.77
(
0.94%
)
Post# of 15274
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

parkourstar

Send PM Follow Ignore
Followers 0
Posts 659
Boards Moderated 0
Alias Born 02/01/2018

parkourstar

Re: mog1962 post# 14969

Friday, 01/11/2019 5:46:43 PM

Friday, January 11, 2019 5:46:43 PM

Post# of 15274
Oh, you talking about this:

http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e22206

"A pilot randomized sham-controlled trial of MC5-A scrambler therapy in the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN)...

...Conclusions: We observed no difference between sham and real ST [scrambler thaerapy] treatment in CIPN."

My, that worked out WELL, didn't it!

Even more interesting is in the disclosures:

https://coi.asco.org/Report/ViewAbstractCOI?id=227731

"Thomas J. Smith...

Travel, Accommodations, Expenses - GeoMC"

What? No CTTC???

ROFLMAO!









ROFLMAO!!!
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up